PPD, Inc. (Nasdaq: PPDI) today confirmed that Takeda Pharmaceutical Company Limited has submitted a new drug application to the U.S. Food and Drug Administration for marketing approval of alogliptin (SYR-322) and ACTOS(R) (pioglitazone HCl) in a single tablet for the treatment of type 2 diabetes.
The details can be read here.
No comments:
Post a Comment